Fabrication of poly(γ-glutamic acid)-based biopolymer as the targeted drug delivery system with enhanced cytotoxicity to APN/CD13 over-expressed cells

References

• Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436–46
   PubMed Web of Science ®Google Scholar
• O'reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926–8
   PubMed Web of Science ®Google Scholar
• Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359–64
   PubMed Web of Science ®Google Scholar
• Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560–4
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–31
   PubMed Web of Science ®Google Scholar
• Soudy R, Ahmed S, Kaur K. NGR peptide ligands for targeting CD13/APN identified through peptide array screening resemble fibronectin sequences. ACS Comb Sci 2012;14:590–9
   PubMed Web of Science ®Google Scholar
• Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002;62:867–74
   PubMed Web of Science ®Google Scholar
• Liu F, Li M, Liu C, et al. Tumor-specific delivery and therapy by double-targeted DTX-CMCS-PEG-NGR conjugates. Pharmaceutical Res 2014;31:475–88
   PubMed Web of Science ®Google Scholar
• Bieker R, Kessler T, Schwoppe C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009;113:5019–27
   PubMed Web of Science ®Google Scholar
• Chen KJ, Tang L, Garcia MA, et al. The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles. Biomaterials 2012;33:1162–9
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688–701
   PubMed Web of Science ®Google Scholar
• Feng Z, Li W, Xue X, et al. A novel GAP460 biopolymer for use as a carrier in drug-delivery applications. J Biomater Sci Polym Ed 2011;22:2023–40
   PubMed Web of Science ®Google Scholar
• Ye H, Jin L, Hu R, et al. Poly(γ,l-glutamic acid)–cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 2006;27:5958–65
   PubMed Web of Science ®Google Scholar
• Geng X, Ye H, Feng Z, et al. Synthesis and characterization of cisplatin-loaded, EGFR-targeted biopolymer and in vitro evaluation for targeted delivery. J Biomed Mater Res A 2012;100:2839–48
   PubMed Web of Science ®Google Scholar
• Xie Y, Aillon KL, Cai S, et al. Pulmonary delivery of cisplatin–hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm 2010;392:156–63
   PubMed Web of Science ®Google Scholar
• Yan X, Gemeinhart RA. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J Control Release 2005;106:198–208
   PubMed Web of Science ®Google Scholar
• Abdul-Ahad P, Webb G. Quantitative structure activity relationships for some antitumor platinum (II) complexes. Int J Quantum Chem 1982;21:1105–15
   Web of Science ®Google Scholar
• Bays E, Tao L, Chang C-W, Maynard HD. Synthesis of semitelechelic maleimide poly(PEGA) for protein conjugation by RAFT polymerization. Biomacromolecules 2009;10:1777–81
   PubMed Web of Science ®Google Scholar
• Yamaguchi F, Ogawa Y, Kikuchi M, et al. Detection of γ-polyglutamic acid (γ-PGA) by SDS-PAGE. Biosci Biotechnol Biochem 1996;60:255–8
   PubMed Web of Science ®Google Scholar
• Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Seminars Cancer Biol 2005;15:378–86
   PubMed Web of Science ®Google Scholar
• Kleinman HK, McGarvey ML, Liotta LA, et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982;21:6188–93
   PubMed Web of Science ®Google Scholar
• Orkin RW, Gehron P, McGoodwin EB, et al. A murine tumor producing a matrix of basement membrane. J Exp Med 1977;145:204–20
   PubMed Web of Science ®Google Scholar
• Vukicevic S, Kleinman HK, Luyten FP, et al. Identification of multiple active growth factors in basement membrane matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 1992;202:1–8
   PubMed Web of Science ®Google Scholar
• Montalbetti CAGN, Falque V. Amide bond formation and peptide coupling. Tetrahedron 2005;61:10827–52
   Web of Science ®Google Scholar
• Sharma G, Kumar R, Chakraborti AK. A novel environmentally friendly process for carbon–sulfur bond formation catalyzed by montmorillonite clays. J Mol Catal A: Chem 2007;263:143–8
   Web of Science ®Google Scholar
• Ravi S, Krishnamurthy VR, Caves JM, et al. Maleimide-thiol coupling of a bioactive peptide to an elastin-like protein polymer. Acta Biomater 2012;8:627–35
   PubMed Web of Science ®Google Scholar
• Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008;69:1–9
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387–92
   PubMed Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Revi 1995;17:31–48
   Web of Science ®Google Scholar
• Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001;3:964–75
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364–6
   PubMed Web of Science ®Google Scholar
• Trepel M, Pasqualini R, Arap W. Chapter 4. Screening phage-display peptide libraries for vascular targeted peptides. Methods Enzymol 2008;445:83–106
   PubMed Web of Science ®Google Scholar
• Yoshihara T, Niimoto M, Hirai T, et al. Combination chemotherapy with cis-diamminedichloroplatinum (CDDP) and other anticancer agents for patients with advanced esophageal cancer. Gan To Kagaku Ryoho 1985;12:1286–93
   PubMedGoogle Scholar
• McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;8:10–16
   PubMed Web of Science ®Google Scholar
• Mansour HH, Hafez HF, Fahmy NM. Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. J Biochem Mol Biol 2006;39:656–61
   PubMedGoogle Scholar